Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder, Other Experts in Psychedelics Discussions

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference; the title of the panel is “Open Minds: Innovations in Consciousness, Psychedelics & Mental Health.” The SXSW event is slated for March 10–19, 2023, and will be held in Austin, Texas. The panel that Drysdale and Chopra are participating on is scheduled for March 12 at 11:30 a.m. CT. According to the announcement, other panel members include Cristie Strongman MA, EdM, a psychotherapist at the Multidisciplinary Association for Psychedelic Studies (MAPS), and Gabriella Wright, cofounder of the Never Alone Alliance. The panel members will be exploring the connection between consciousness, mental health and psychedelic therapeutics along with the need for humanity to focus on the internal work required to heal. These same industry experts are also part of an upcoming miniseries, titled “Open Minds: Exploring Psychedelic Medicine. ”The six-part program will look at topics such as consciousness, the experience of using psychedelic treatments, the current research landscape and what the future of mental healthcare may look like. The miniseries also features researcher Dennis McKenna, who has conducted interdisciplinary research on the ethnopharmacology of Amazonian traditional medicines for more than 40 years; Bryan Johnson, founder and CEO of Kernel; Keith Ferrazzi, founder and chair of Ferrazzi Greenlight; and Adam Strauss, comedian and psychedelic advocate. Cybin is a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and the Chopra Foundation is a not-for-profit organization dedicated to improving health and well-being.

 To view the full press release, visit

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists and on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Cybin Inc. CYBN. Bookmark the permalink.

Comments are closed.